SAO PAULO and GOIANIA, Brazil – Celesio AG announced today that Dr Alexander Triebnigg (52) has taken over the management of the Brazilian pharmaceutical wholesaler anpharma, a subsidiary of the German Celesio AG, as of 1 July 2 013.
Triebnigg has gained many years of leadership experience in the Brazilian pharma market: From 2006 to 2010 as General Manager of Novartis Pharma and as of 2011 as President of Novartis Group, leading all six business divisions in Brazil.
Prior to this he held the positions of General Manager of Novartis Pharma Portugal, General Manager of Fisher Scientific Germany & Central and Eastern Europe and various commercial leadership positions at Merck & Co. in Austria, Belgium and within the Region Europe.
Alexander Triebnigg is a medical doctor and studied management at the Harvard Business School. He is married with three children.
Nikolaus Vogler (50), who in addition to his role as Director of Operations took on the duties of the chairman of the management board in May of last year, will concentrate on his responsibilities in operations (IT, SCM and Purchasing/Procurement) again, as planned.
About Celesio Group
As a leading international trading company and provider of logistics and services in the pharmaceutical and healthcare sector, Celesio takes a proactive and preventive approach to ensuring that patients receive the products and support that they require for optimum care. With 39,000 employees, we operate in 16 countries around the world. Every day, we serve over 2 million customers – at 2,200 pharmacies of our own and 4,100 participants in our brand partnership schemes. With around 140 wholesale branches, we supply approximately 65,000 pharmacies and hospitals every day with up to 130,000 pharmaceutical products. Our services benefit a patient pool of about 15 million per day.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.